Article
Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data.
JCO oncology practice - 1 Jan 2024
Scott Jeffrey A, Lennerz Jochen, Johnson Melissa Lynne, Gordan Lucio N, Dumanois Robert H, Quagliata Luca, Ritterhouse Lauren L, Cappuzzo Federico, Wang Brandon, Xue Mei, Vasudevan Anupama, Varughese Prateesh, Vaidya Varun, Gart Mike, Dorrow Natalie, Gierman Hinco J, Choksi Rushir J
Abstract excerpt
PURPOSE: Identification and targeting of actionable oncogenic drivers (AODs) in advanced non-small-cell lung cancer (NSCLC) has dramatically improved outcomes. However, genomic testing uptake is variable and hampered by factors including slow turnaround time, frequently resulting in initial non-tyrosine kinase inhibitor (TKI) treatment. We investigate how this behavior affects outcomes. METHODS: This...
Topics
Join the communities discussing this publication.